The long noncoding RNA HOXA11-AS reveals abnormal expression in numerous human diseases. However, its function and biological mechanisms remain unclear in Preeclampsia (PE). In this study, we report that HOXA11-AS was significantly downregulated in preeclampsic placental tissues and could contribute to the occurrence and development of Preeclampsia. Silencing of HOXA11-AS expression could significantly suppress trophoblast cell growth and migration, whereas HOXA11-AS overexpression facilitated cell growth in HTR-8/SVneo, JEG3 and JAR cell lines. RNA-seq analysis also indicated that HOXA11-AS silencing preferentially regulated numerous genes associated with cell proliferation and cell migration. Mechanistic analyses showed that HOXA11-AS could recruit Ezh2 and Lsd1 protein, and regulate RND3 mRNA expression in nucleus. In cytoplasm, HOXA11-AS modulate HOXA7 expression by sponged miR-15b-5p, thus affecting trophoblast cell proliferation. Together, these resulting data confirm that aberrant expression of HOXA11-AS is involved in the occurrence and development of Preeclampsia, and may act as a prospective diagnosis and therapeutic target in PE.
maintained in proper media containing 10% FBS for 10-14 days, during which the medium was replaced every 4 days. Colonies were then fixed with methanol and stained with 0.1% crystal violet (Sigma) in PBS for 30 min. Colony formation was determined by counting the number of stained colonies.
BrdU experiments were performed by using a BrdU Cell Proliferation Assay Kit (Millipore, Cat.No.2750) following the protocol. The higher OD reading represents the higher BrdU concentration in each sample.
EdU assay was implemented as a complementary method in order to authenticate the proliferation level. Usually, we exploit the 5-ethynyl-2-deoxyuridine labeling/detection kit (Ribobio, Guangzhou, China) to evaluate cell proliferation, following the manufacturer's manual.
Flow-cytometric analysis of cell cycle and apoptosis.
After transfecting cells with siRNAs or plasmid, we performed FITC-Annexin V and Propidium iodide (PI) staining by using the FITC-Annexin V Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA) following manufacter's instruction. Cell cycle level was determined by propidium oxide staining using the Cycle TEST PLUS DNA Reagent Kit (BD Biosciences, Franklin Lakes, NJ, USA) following the protocol and analyzed by FACScan. The ratio of the cells in G0/G1, S and G2/M phase were calculated and compared.
Transwell assays.
The ability of cell migration and invasion was detected and analyzed by transwell assays as previously reported in Xu et al [31] . 24-well chambers were placed into the upper chamber of an insert with 8µm pore size polycarbonate membrane (Millipore, Billerica, MA, USA). Medium containing 15% FBS was added to the lower chamber. After incubation for 24-48 h, the cells on the upper membrane were removed with cotton swab. Cells that migrated or invaded through the polycarbonate membrane were stained with methanol and 0.1% crystal violet. Experiments were conducted repeatedly three times.
Western blot assays.
WB assays were conducted as previously reported in Xu et al [31] , and the following primary antibodies were used respectively: Anti-EZH2, Anti-LSD1, Anti-AGO2 (Millipore, USA), Anti-RND3 and Anti-HOXA7 from Proteintech (WuHan, China).GAPDH (Cell Signaling, San Jose, CA, USA) antibody was used as the control.
RNA-seqbioinformatic analysis.
The RNA-seq experiments were conducted by Wuhan Genomics Institute (Wuhan, China). Culture cells which were treated were extracted. To stablish the mRNA-seq library, the cDNAs were fragmented via nebulization following the protocol.
Chromatin immunoprecipitation assays (ChIP).
Chromatin immunoprecipitation (ChIP) assays were conducted as previously described in Xu et al [31] . According to the manual, experiments were performed by using EZ-CHIP KIT (Millipore, USA). Relevant antibodies against H3K27me3, H3K4me2 and other target proteins were purchased from Millipore. The primer sequences of gene promoter were summarized in Supplementary Table polymerase according to the protocol. Luciferase activity was measured by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Briefly, 1×10 5 HTR-8/SVneo cells were plated in 24-well plates for 36h. After 48 hours post-transfection, the cells were obtained and lysed for further experiments. The relative luciferase activity was normalized with renilla luciferase activity.
Statistical analysis
All statistical analyses in our experiment were performed by using SPSS 20.0 software (IBM, SPSS, USA). These resulting data was represented as the mean ± SD. Statistical significance were ascribed at P<0.05(*) or P<0.01(**). Each experiment was repeated at least three times independently.
Result

HOXA11-AS is downregulated in human preeclampsic tissues.
The expression level of HOXA11-AS was analyzed in 60 preeclamptic tissues and normal tissue samples by qRT-PCR. We found that the HOXA11-AS expression was significantly downregulated in preeclampsic tissues (Figure1A). The detailed clinical characteristics of the patients who meet criteria were listed in table 1. In addition, we discovered that there were no significant differences between preeclampsia and the normal in gestational age and maternal age. (P>0.05). On the contrary, there were significant differences in systolic blood pressure, diastolic blood pressure and body weight of infant between preeclampsia and the normal (P<0.05).
HOXA11-AS regulates trophoblast cell proliferation and migration in vitro.
Since human lncRNAs play essential roles in various cellular processes, we detected the expression of HOXA11-AS in four trophoblast cell lines and another two cell lines related to pregnancy, including HTR-8/SVneo, BeWo, JEG-3 and JAR, WISH and HUVEC-C. As shown in figure 1B , we found that the relative HOXA11-AS level in HTR-8/SVneo cells was higher than that in other cell lines, whereas the expression levels of HOXA11-AS in BeWo, JEG3 and JAR cell lines were relatively lower compared to those in WISH and HUVEC-C cell lines.
To explore potential role of HOXA11-AS in trophoblast cells, we performed overexpression and knowdown model of HOXA11-AS in vitro. It was found that the expression levels of HOXA11-AS were exogenously influenced by specific siRNAs and overexpression plasmid in HTR-8/SVneo, JEG3 and JAR cell lines ( figure 1C and 1D ). Then we performed MTT and Colony formation assays to illustrate the effect of HOXA11-AS on the proliferation of HTR-8/SVneo, JEG3 and JAR trophoblast cells. The resulting data revealed that silencing of HOXA11-AS significantly retarded cell growth compared with that of the controls, while upregulation of HOXA11-AS could enhance cell proliferation (Figure 2A and 2B ). In addition, Ethynyl deoxyuridine (EdU) staining assays and BrdU assays also demonstrated that HOXA11-AS knockdown inhibited trophoblast cells proliferation; however, HOXA11-AS overexpression boosted the rate of proliferating trophoblast cells ( Figure 2C and 2D ). These data indicate that down-regulated HOXA11-AS might play the role as a suppressor in the inhibition of trophoblast cell proliferation.
Furthermore, transwell assays confirmed that silencing of HOXA11-AS significantly inhibited trophoblast cell migration and invasion compared with the si-NC treatment ( Figure 3A) . In contrast, upregulated HOXA11-AS could stimulate cell migration and invasion ( Figure 3A) .
Effect of HOXA11-AS on cycle and apoptosis in vitro.
Because cell proliferation assays cannot thoroughly reflect cell cycle changes, we next performed flow cytometry analysis to detect whether the cell cycle progression was affected after HOXA11-AS knockdown. The results revealed that the cells transfected with specific siRNAs promoted cell accumulation in the G0-G1 phase compared with that treated with si-NC. In contrast, HOXA11-AS overexpression could reduce cell cycle accumulation in G0-G1 phase ( Figure 3B ).
Also, flow cytometry assays were performed to investigate whether knockdown of HOXA11-AS affected the cell apoptosis. The results showed that the ratio of total apoptotic cells were dramatically increased in cells transfected with siRNAs in the HTR-8/SVneo ( Figure 3C ). Similarly, we conducted flow cytometry assays to detect the protein expression level of cleaved-caspase, which further confirmed that the apoptosis level was increased after HOXA11-AS knowdown ( Figure 3D ). These findings suggest that HOXA11-AS promotes proliferation and inhibits apoptosis in trophoblast cells.
Gene expression profiling
To investigate the HOXA11-AS-associated pathway on an unbiased basis in Preeclampsia, we conducted RNA-seq and evaluated the gene expression profiles of HTR-8/SVneo cells transfected with siRNAs against HOXA11-AS. After knockdown of HOXA11-AS, 131 mRNAs showed at least a 2-fold increased abundance, whereas a total of ( ≤ 2-fold) of 99 genes showed decreased abundance ( Figure 4A ). GO analysis showed many significant biological processes were involved in cell proliferation, migration, as well as apoptosis ( Figure 4B ). Among all the enriched genes, there are many famous proliferation-related and migration-associated genes, such as TNFSF9, TFPI2, CA9, IFITM1, TMEM158, RND3, ESM1, NAMPT1, HOXA7, PSAT1, CPA4, MEST, OLR1, etc. We suspected that some altered genes might induce the occurrence and development of Preeclampsia. The expression changes of these genes, therefore, were selectively demonstrated by qRT-PCR in HOXA11-AS depleted and/or HOXA11-AS overexpressed HTR-8/SVneo cells and HOXA11-AS overexpressed JAR cells ( Figure 4C and 4D). Lastly, RND3 and HOXA7 have been identified as candidate factors involved in cell proliferation, apoptosis, and migration; therefore, we selected RND3 and HOXA7 for further study.
HOXA11-AS could recruit Lsd1 and Ezh2 in nucleus, thus epigenetically silencing of RND3.
To further explore the potential biological mechanisms of HOXA11-AS medicated regulation in trophoblast cells, we first performed subcellular fractionation assays to assess the distribution of HOXA11-AS in nuclear and cytoplasmic fractions in HTR/SVneo, JEG-3 and JAR cells. As shown in figure 5A , approximately 70% of HOXA11-AS is located in the trophoblast nucleus, and 30% of HOXA11-AS is in the cytoplasm. Therefore, these findings indicated that HOXA11-AS might play an essential role in transcriptional regulation. Then, we employed bioinformatics analysis to predict possibilities of RNA binding proteins, including Ezh2 (H3K27me3), Suz12 (H3K27me3), Lsd1 (H3K4me2), Dnmt1, Hur, Stau1 and Ago2 (http://pridb. gdcb.iastate.edu/RPISeq/references. php) [32] . As shown in Figure 5B , HOXA11-AS may interact with Ago2, Ezh2 (H3K27me3) and Lsd1(H3K4me2) in trophoblast cells. And previous studies have reported that HOXA11-AS could recruit Ezh2 and Lsd1 to epigenetically silenced targets in many tumor cell lines
To examine that the interaction probabilities of HOXA11-AS with target proteins, we performed RIP assays with these antibodies. There was a substantial enrichment in RIPs of Ezh2, Lsd1 and Ago2 in HTR-8/SVneo ( Figure 5C ). Additionally, we also conducted RIP assays in JEG3 and JAR cells which were transfected with overexpression plasmid of HOXA11-AS. Our results demonstrated that HOXA11-AS directly interacted with Ezh2, Lsd1 and Ago2 ( Figure 5C ). Furthermore, RNA pull down assays further confirmed that HOXA11-AS could interacted with Ezh2, Lsd1, and Ago2 in HTR-8/SVneo cells ( Figure 5D ). These resulting data demonstrated that HOXA11-AS could directly bind with Lsd1, Ezh2 and Ago2 in trophoblast cells. Previous studies have reported that Lsd1 and Ezh2 were negative regulators of transcription via the trimethylation of histone 3 lysine 4 (H3K4me2) and the trimethylation of histone 3 lysine 27 (H3K27me3), respectively [33] [34] [35] . Therefore, we further explored the mechanism correlation among Ezh2, Lsd1 and HOXA11-AS using experimental methods.
We first suppressed the expression of Lsd1 and Ezh2 by effective siRNAs, respectively. The protein level of RND3 was significantly upregulated after transfected with EZH2 siRNAs and/or LSD1 siRNAs in HTR-8/SVneo cells ( Figure 5E ). Then, we hypothesized that HOXA11-AS may recruit Ezh2 and Lsd1 to RND3 promoter region, resulting in trimethylation of H3K27 and/or H3K4 in this region. Therefore, we performed ChIP assays to detect the enrichment of Ezh2 and H3K27me3, Lsd1 and H3K4me2 in the promoter region of RND3. As shown in the figure 5F , the results determined that Lsd1 and Ezh2 protein could be directly recruited to the promoter region of RND3 gene, thus silencing HOXA11-AS. Silencing of HOXA11-AS further suppressedEzh2-mediated H3K27me3 demethylation and Lsd1-mediated H3K4me2 demethylation.
Our previous studies [31] have reported that the expression level of RND3 was significantly increased in preeclampsic placental tissues compared to that in the controls. In this study, we also found that overexpression of RND3 could inhibit cell proliferation in HTR-8/SVneo and JEG3 cell lines ( Figure 6A-6D) . Overexpression of RND3 could also partly reverse HOXA11-AS-mediated growth promotion ( Figure 6E and 6F) . Together, these data suggest that HOXA11-AS medicated cell growth could be reversed partly through epigenetic suppression of RND3 by binding to Ezh2 and Lsd1 in nucleus of trophoblast cells. HOXA7 expression by sponged miR-15b-5p , thus affecting trophoblast cell proliferation.
HOXA11-AS promotes
Based on the RNA-seq analysis, numerous genes affecting cells phenotype were downregulated after silencing of HOXA11-AS. HOXA7, part of the cluster on chromosome 7, could promote cell proliferation and migration in various cell lines [36] [37] [38] [39] . We next performed Western Blotting assays to further demonstrate the RNA-seq results. As shown in the Figure 7A , we found that the protein level of HOXA7 was significantly upregulated after HOXA11-AS overexpression, whereas the opposite result was found after HOXA11-AS knockdown in HTR-8/SVneo cells. An increasing number of studies have reported that lncRNAs could compete for specific microRNAs (miRNA) in cytoplasm to mediate mRNAs expression, thus further affecting cells phenotype [22] . There is evidence that miRNAs were found predominantly in the cytoplasm by binding to Ago2, which is the fundamental element of the RNA-induced silencing complex. Based on the subcellular fractionation assays and RIP assays ( Figure 5C ), we found that 30% HOXA11-AS were distributed in the cytoplasm and HOXA11-AS could interact with Ago2 protein. Then, we hypothesized whether HOXA11-AS modulate HOXA7 expression levels by sponged specific microRNA in HTR-8/SVneo cells.
To validate this concept, we first conducted bioinformatics analysis and found that miR-15b-5p was predicted to bind to the 3′ UTR of downstream target gene of both HOXA11-AS and HOXA7 ( Figure 7B ). Then, we performed qRT-PCR and the results showed that silencing of HOXA11-AS significantly upregulated the expression of miR-15b-5p; in contrast, the miR-15b-5p level was decreased after HOXA11-AS overexpression. Further experiments indicated that RNA and protein levels of HOXA11-AS and HOXA7 were significantly reduced after transfected with miR-15b-5p mimics ( Figure 7C ). Next, we further explored the functions of miR-15b-5p in trophoblast cells. Diverse luciferase genes, including HOXA11-AS, mutant HOXA11-AS, 3′ UTR of HOXA7 and mutant 3′ UTR of HOXA7, were cloned and then co-transfected with miR-15b-5p in HTR-8/SVneo cells, respectively. Interestingly, we found that the relative luciferase activity of reporters of HOXA11-AS and 3′UTR of HOXA7 were significantly abolished after treatment by miR-15b-5p ( Figure 7D ). In contrast, the relative luciferase activity on mutant reporters of both HOXA11-AS and 3′UTR of HOXA7 showed no effect after treatment by miR-15b-5p ( Figure 7D ). Therefore, these resulting data demonstrated that miR-15b-5p could bind to both HOXA11-AS and HOXA7 gene. Moreover, MTT and BrdU assays indicated that knockdown of HOXA7 could inhibit proliferation in HTR-8/SVneo cells, and silencing of HOXA7 could reverse HOXA11-AS-induced cell proliferation ( Figure 7E ).
Discussion
Recent studies have indicated that plenty of lncRNAs have critical roles in PE. For example, the proverbial lncRNA MALAT1 were recently determined to affect trophoblast cells proliferation, apoptosis, thus promoting PE development [16] . Our previous study also demonstrated that lncRNA SPRY4-IT1 and MEG3 modulate trophoblast cell proliferation, apoptosis as well as tube formation, invasion and migration in this disorder [14, 40, 41] . Moreover, other lncRNAs, including ATB, Uc.187, RPAIN and so on, were reported to regulate trophoblast cell growth or/and invasion or/and apoptosis in PE [17, 18, 42] . Therefore, more and more potential PE-associated lncRNAs need to be identified, the functions of which require further exploration for their underlying biological mechanisms.
In our study, we discovered that the level of HOXA11-AS was significantly downregulated in preeclampsic tissues compared with those in normal tissue samples, thus suggesting that HOXA11-AS might play an essential role in PE progression. Our data also revealed that knockdown of HOXA11-AS could impair trophoblast cell proliferation and migration in vitro, whereas HOXA11-AS overexpression could promote cell proliferation and migration. In order to investigate the HOXA11-AS -related pathway and downstream genes in PE, we conducted RNA transcriptome sequencing after transfecting target cell line with specific siRNAs against HOXA11-AS, and GO analysis suggested that gene expression profiles were primarily proliferation and migration associated. Previous studies have determined that lots of lncRNAs could bind with various chromatin modifying enzymes to regulate related genes expression at epigenetic level [43] . For instance, the pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 to repress LATS2 and RRAD in non-small cell lung cancer [44] , and LncRNA TUG1 was involved in cell proliferation of small cell lung cancer by regulating LIMK2b via EZH2 [45] . Our resulting data also revealed that HOXA11-AS could recruit and bind to two histone methylation modification complexes, including EZH2 and LSD1 in nucleus, thus silencing genes expression. Further experiments were performed, indicating that these targets were affected through promoter H3K4me2 demethylation and H3K27me3 demethylation in trophoblast cells.
RND3/ RhoE is a small GTPase that could exhibit biological functions as suppressor genes in numerous diseases [46] [47] [48] [49] , thus inhibiting multiple cellular processes, such as actin cytoskeleton dynamics, cell cycle [46] , migration, invasion [50] , and apoptosis [46, 51] . However, the functions of RND3 in the pathological process of PE was still unclear. Our results revealed that HOXA11-AS could contribute to the downregulated expression of RND3 by histone methylation in trophoblast cells. These results suggested that HOXA11-AS could bind to Ezh2 and Lsd1, thus epigenetically silencing RND3 in nucleus of trophoblast cells.
HOX genes, a highly conserved subgroup of the homeobox superfamily, are spatially and temporally regulated during embryonic development [52] . Abnormal expression of HOXB7 [53] and HOXB13 [54] have been reported to regulate many processes including apoptosis, receptor signaling and differentiation in myriad of disorders [55] . In our study, we found that low levels of HOXA7 could affect proliferation in trophoblast cell lines, which implies that the post-transcriptional regulation of HOXA7 was partly mediated by HOXA11-AS in development of PE, through sponging miR-15b-5p in cytoplasm, thus accelerating trophoblast cell growth. Furthermore, Sun et al [29] has demonstrated that HOXA11-AS could promote gastric cancer tumorigenesis through sponging miR-1297. These findings demonstrated that HOXA11-AS simultaneously compete for miR-1297 and miR-15b-5p.
In brief, HOXA11-AS facilitates cell proliferation and migration by epigenetically regulating RND3 in nucleus. And it could promote trophoblast cell growth through sponging miR-15b-5p in cytoplasm. Our results indicated that HOXA11-AS could exhibit diverse biological regulatory mechanisms in PE, which might act as a prospective diagnosis and therapeutic target for PE ( Figure  8 ). Table S1 . Sequence of primers and siRNAs. Table S2 and S3. Analysis of the RNA transcriptome sequencing data.
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